ABSTRACT. Enhanced Na+-linked nutrient absorption has been demonstrated in the cystic fibrosis bowel and may contribute to the dehydration of the luminal contents. The ability of loperamide to inhibit glucose transport was therefore assessed in jejunal biopsy specimens from children with cystic fibrosis by measuring the increased shortcircuit current associated with active glucose absorption using a mini-Ussing chamber technique. The presence of loperamide in the luminal solution reduced the rise in shortcircuit current induced by glucose over the range of concentrations tested (2.5 to 40 mmol. L-'). This finding suggests that the enhanced Na+ absorption, which is a feature of cystic fibrosis, is amenable to treatment and can be restored to normal levels. This result may have therapeutic implications for gastrointestinal function and may be applicable to other tissues where similar therapeutic approaches to reduce Na+ and thus water absorption are being pursued. (Pediatr Res 35: 354-356, 1994) Abbreviations CF, cystic fibrosis SCC, short-circuit current CF is a multiorgan disease that is characterized by abnormal ion transport across epithelia (1). It is now well established that, in CF, epithelia that normally secrete C1-, e.g. those lining the intestine and the airways, fail to do so, (1-7) and it has been suggested that this abnormality is responsible for the excessive dehydration of the luminal contents. The recent discovery of the C F gene (8) and evidence that its product, CF transmembrane conductance regulator, can act as a C1-channel (9) has led to emphasis being placed on this aspect of epithelial ion transport dysfunction in CF. However, failure of C1-secretion is not the only abnormality present in CF epithelia. Increased Na+ absorption has also been reported in both the airway (10) and the intestine, (4) (5) (6) and this increased absorption is accompanied in the small intestine by enhanced Na+-linked nutrient absorption (1 1). This increased absorption will also contribute to luminal dehydration and indeed may prove to be of greater clinical significance than impaired C1-secretion, particularly in the airway that is capable of a normal response to Ca2+-mediated secretagogues, only failing to secrete Cl-when challenged by cyclic AMP-mediated agonists (12) . Thus, therapy directed at reducing the enhanced absorption in CF may prove, in the shortterm at least, more effective than attempts to activate secretion.
The antidiarrheal agent loperamide inhibits Na+-linked nutrient absorption in rat small intestine, (13) and the aim of the 3 present study was to determine whether this agent could reduce the enhanced absorption in the CF bowel.
MATERIALS AND METHODS
Patients. Peroral jejunal biopsy specimens were obtained from 1 1 children with CF who were undergoing investigation for chronic diarrhea that was unresponsive to changes in pancreatic enzyme supplementation and that was not associated with evidence of enteropathy. The diagnosis of CF was confirmed by at least two successive abnormal sweat tests, and a genetic analysis was performed to identify the defect in the CF gene product. Five of the control group of six patients and three of the test group of five patients were AFS08 homozygotes. The other three children were AF508 heterozygotes, two with undefined mutations (one control, one test), both of whom had meconium ileus at diagnosis, and one with the R553X mutation (test group). All children were pancreatic insufficient. The mean age ofthe control group was 8.3 y (range, 0.4 to 18.5 y), and the mean age of the test group was 4.3 y (range, 1.0 to 9.0 y). Intestinal morphology was normal in all cases.
Esperitnentalproccd~tre. The electrical activity of biopsy specimens was measured as described previously (3) . Each tissue was mounted as a sheet (exposed area, 3 mm2) in a mini-Ussing chamber and incubated at 37°C with Krebs bicarbonate saline gassed with 95% 0215% CO2. The serosal solution contained 10 mmol . L-' glucose and the mucosal solution equimolar mannitol. The potential difference was measured with salt bridge electrodes connected by way of calomel half cells to a differential input electrometer whose output was displayed on a chart recorder (Linseis L6512, Selb, Germany). Current was applied across the tissue by conductive plastic electrodes. Tissue resistance was determined from the change in potential difference induced by a 10-PA current pulse, corrected for the fluid resistance. The SCC was then calculated from potential difference and resistance measurements with Ohm's law. After 10 min of stabilization, potential difference and resistance were measured at I-min intervals. Each tissue was initially challenged with acctylcholine (lo-' mol. L-I in serosal solution), which was added after 5-min basal readings. The serosal solution was replaced, and the tissue was allowed to restabilize. In the control tissues, glucose was added sequentially to the mucosal solutions to give concentrations of 2.5 to 40 mrno1.L-I, and the rise in SCC was taken as the difference between the maximum value achieved at each concentration and the value immediately before the start of the glucose application. The mucosal solution was then replaced, and the procedure was repeated with cquimolar concentrations of mannitol to assess the effect of the increased osmolarity resulting from the mucosal addition of glucose. In the test tissues, the effects of 10 mmol. L-' concentrations of glucose and mannitol were tested before loperamide was added. After washing out, loperamide (1.9 x 1 0-4 mol . L-') was added to the mucosal solution, followed 5 min later by serial additions of glucose as in the control experiments. The mucosal solution was then re-placed, and the procedure was repeated with mannitol in the presence of loperamide. The experimental protocol is illustrated in Figure 1 , which shows data from a control tissue and a test tissue.
To assess the rise in SCC associated with active glucose absorption, the change in SCC induced by each concentration of mannitol was subtracted from the increase in SCC caused by the same concentration of glucose.
Expression of results. Results are expressed as mean values f 1 SEM of the mean of the number of observations indicated, and the significance of loperamide action was assessed by an unpaired I test.
Chemicals 
RESULTS
The increase in SCC associated with active glucose absorption in jejunal biopsy specimens from children with CF was greater than that observed in non-CF tissues. When data from all the biopsy specimens we studied were analyzed, the rise in SCC induced by 10 mmol. L-I glucose was 44.1 f 4.6 (n = 30) PA.
in CF tissues compared with 24.3 f 3.1 (n = 48) P A . c~-~ in non-CF tissues ( p < 0.001), confirming, with an increased number of patients, previous observations (1 1).
In the CF tissues used in the present study, the basal SCC was similar in the control (n = 6) and test (n = 5) groups (control, PA.crn-* observed in biopsy specimens from children without CF.
The effects of glucose and mannitol on the SCC generated by CF intestine are illustrated in Figure 1 . In the test group the changes in SCC induced by 10 mmo1.L-I glucose (34.1 f 5.9 PA .~m -~) and 10 mmol .L-' mannitol (-8.6 f 0.7 PA.cm-?) were not significantly different from those observed in the control group (glucose, 39.9 f 2.9 PA. ~m -~; mannitol, -13.7 a 3.6 PA.
~m -~, p > 0.05 in both cases). The effect of glucose, corrected for its osmotic action, is expressed as a percentage of the response to 10 mmo1.L-I glucose in the absence of loperamide to avoid any bias from the fact that the glucose-dependent rise in SCC was slightly lower in the test group. Changes in SCC induced by glucose in the control group are similarly related to the 10 mmol. L-I value.
Loperamide (1.9 x mol. L-I) reduced the basal SCC of the five test tissues by 6.2 f 0.7 ~A . c m -~ but had no effect on the decrease in SCC induced by mannitol. In the five test tissues, 10 mmol. L-' mannitol reduced the SCC by 8.6 f 0.7 PA. cm-2 when loperamide was absent and by 6.6 + 1. Loperamide reduced the rise in SCC associated with the active absorption of glucose to values that were 66.2 f 0.9% of those observed at the same concentrations in control tissues (Fig. 2) . The degree of inhibition did not alter with the concentration of glucose.
The apparent transport constant and the V,,, were calculated with both the Eadie-Hofstee plot (14) and the direct linear plot (15) . These two methods produced values that did not differ Glucose concn ( r n r n o l ,~-~) Fig. 2 . Effect of loperamide (1.9 x mo1.L-I in rnucosal solution) on the rise in SCC associated with active glucose absorption in jejunal biopsy specimens from children with CF. Glucose was added to the mucosal solution to give the concentrations indicated, and the osmotic component of the response was assessed with equimolar concentrations of rnannitol. The effect of glucose, corrected for its osmotic action. is expressed as a percentage of the SCC change induced by 10 mmo1.L-' glucose in the absence of loperamide. Each point represents the mean + SE of the mean of six control (0) and five test ( 0 ) tissues, and the significance of loperamide action was determined with an unpaired t test. *, p < 0.05; **, p < 0.01.
significantly ( p > 0.05 for both indices). The kinetic analysis This action may represent an inhibition of basal Na+ transport, revealed that loperamide reduced the V,,, without affecting the as has been observed in rat small intestine (1 3). transport constant (Table 1) .
In the normal intestine, loperamide, in addition to its antiabsorptive actions, is a potent inhibitor of C1-secretion, (19) and this inhibition contributes to its effectiveness as an antidiarrheal DISCUSSlON anent. However. because the CF intestine lacks the abilitv to The increased electrical activity induced by glucose is directly related to its rate of active absorption (16) . Thus, an enhanced response to glucose in jejunal biopsy specimens from patients with CF (1 1) suggests that active glucose absorption by the intestine is increased in the disease, a finding supported by in vivo perfusion studies demonstrating greater glucose uptake by the jejunum of patients with CF (17) . A limited number of flux determinations performed on larger intestinal sheets suggest that basal Na' absorption may also be increased in CF (4) (5) (6) .
The basis of the increased absorption in CF is unclear. It has been suggested that the lack of normal C1-channel activity in the luminal membrane of CF enterocytes could cause a hyperpolarization that would provide a greater driving force for Na' and nutrient entry (I I). Such an explanation cannot, however, account for enhanced absorption by the CF airway where direct measurement of the apical membrane potential has revealed a decrease, rather than an increase, in CF tissues (18) .
Net fluid movement across epithelia is determined by net solute transport, which in turn depends on the balance between absorptive and secretory processes. Hence, an enhanced absorption, particularly if coupled to impaired secretion, will lead to a dehydration of the luminal contents, which may contribute to clinical symptoms. This situation can be improved either by activating secretory mechanisms or by reducing absorption, and the present study reveals that loperamide, an agent currently in clinical use, can inhibit absorptive processes in the intestine (Fig.  2) .
The ability of loperamide to inhibit intestinal absorption has been established with tissue from the rat (13) . Loperamide in the mucosal solution was found to reduce the Na'-linked absorption of nutrients determined both directly and as an increase in transintestinal electrical activity. Kinetic analysis of the data demonstrated that this effect resulted from a decrease in V,,,, and, because loperamide was much less effective when the Na' gradient was reduced, it was suggested that it could interfere with the interaction of Na' with its site on the nutrient cotransporter, preventing it from using the energy from the Na+ gradient. In jejunal biopsy specimens from patients with CF, the inhibitory actions of lopemmide similarly result in a reduced V,,, (Table  I) , which is consistent with an action limiting the energy available to the cotransporter.
In addition to its actions on nutrient transport, loperamide also reduced the basal SCC in the CF jejunal biopsy specimens. * Transport constant a n d V,,, values were determined with the EadieHofstee plot, a n d a n unpaired I test was used t o assess t h e significance of loperamide action.
secrete C1-(2-7), this aspect of loperamide action will not be of consequence to CF patients. Enhanced Na+ absorption in CF is a feature not only of the intestine but also of the airway (10) . The possibility that reducing this aspect of ion transport dysfunction in CF might alleviate clinical symptoms has been tested by the administration of amiloride, an inhibitor of Na' transport, in aerosol form to patients with CF. The regime was found to slow the rate of deterioration of respiratory function in a small number of adult patients with established chronic lung disease (20) . The present study extends the range of agents that inhibit the enhanced absorption of CF and suggests an alternative approach to treatment of some of the symptoms of the disease.
